BioLink Therapeutics

🚀 At BioLink Therapeutics, Science Meets Purpose. Innovation Meets Urgency.

At BioLink Therapeutics, we are advancing a bold, global vision: to accelerate the discovery of AI-powered small-molecule therapeutics targeting antimicrobial resistance (AMR) and neurodegenerative diseases—two of the most urgent and underserved challenges in medicine today.

At the same time, we are in the process of licensing next-generation, affordable point-of...

🚀 Biolink Therapeutics is on the brink of transforming cancer diagnostics in India and beyond! BioLink is collaborating with a U.S.-based startup to license an innovative, patented, biomarker-driven liquid biopsy platform. This advanced technology enables rapid, point-of-care cancer screening—including lung, breast, colorectal, and prostate cancers—with results available in just 15 minutes.

🛑 While AI-powered cancer detection platforms m...

BioLink Therapeutics' adjuvant molecule is designed to work synergistically with existing antibiotics by targeting the mechanisms that confer resistance in Bacillus subtilis. Instead of directly killing the bacteria, the adjuvant molecule disrupts the bacterial defense systems—such as efflux pumps, biofilm formation, or enzyme-mediated antibiotic degradation—that typically neutralize antibiotic action. By inhibiting these resistance pathw...